Heterogeneity derived from (18)F‐FDG PET/CT predicts immunotherapy outcome for metastatic triple‐negative breast cancer patients

BACKGROUND: Recently, immunotherapy has been used to treat metastatic triple‐negative breast cancer (mTNBC). Basic research has indicated a relation between tumor heterogeneity and the immune response. Tumor heterogeneity derived from (18)F‐FDG PET/CT is a potential predictor of chemotherapy results...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yizhao, Liu, Cheng, Zhao, Yannan, Gong, Chengcheng, Li, Yi, Hu, Shihui, Song, Shaoli, Hu, Xichun, Yang, Zhongyi, Wang, Biyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9089221/
https://www.ncbi.nlm.nih.gov/pubmed/35275444
http://dx.doi.org/10.1002/cam4.4522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9089221/
https://www.ncbi.nlm.nih.gov/pubmed/35275444
http://dx.doi.org/10.1002/cam4.4522

Ejemplares similares